

# Asia Resources Holdings Limited

亞洲資源控股有限公司\*

(incorporated in Bermuda with limited liability)

(stock code : 899)

## ANNOUNCEMENT

This announcement is made pursuant to Rule 13.09 of the Rules (“Listing Rules”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“Stock Exchange”).

The board (“Board”) of directors (“Directors”) of Asia Resources Holdings Limited (“Company”) was informed by one of its wholly owned subsidiaries (namely, Zhejiang Juneng Rosi Pharmaceutical Co., Ltd. (“Zhejiang Subsidiary”, 浙江巨能樂斯藥業有限公司)) that because of certain alleged side-effects which might have been caused by one of the products of Zhejiang Subsidiary, the Zhejiang Subsidiary has since 29 October 2008, on a voluntary basis, temporarily suspended its production operations to facilitate tests and examination of its products to be conducted.

Under the Listing Rules, the Zhejiang Subsidiary falls under the class of “major subsidiary” of the Company.

According to the preliminary report made by the Zhejiang Subsidiary to the Company, on 28 October 2008, about 12 children in Fuzhou (福州), the People’s Republic of China (“PRC”), who had been admitted different drugs together with glucose intravenous fluid manufactured by the Zhejiang Subsidiary, suffered from some side-effects. So far as the Zhejiang Subsidiary is aware, such children currently are now in stable health conditions. The above incidents (“Incidents”) have been reported to the relevant pharmaceutical supervisory administrations in the PRC.

Following the occurrences of the Incidents, the glucose intravenous fluid products manufactured by the Zhejiang Subsidiary and distributed in Fuzhou have been suspended from further use and been subject to testing and examination. So far as the Zhejiang Subsidiary is aware, there have not been any reports that patients in other places, who used the glucose intravenous fluid products manufactured by the Zhejiang Subsidiary, suffered similar or other side-effects.

In the interest of patients and possible patients who may use its glucose intravenous fluid products, the Zhejiang Subsidiary has, since 29 October 2008, on a voluntary basis temporarily suspended its production operations in order to facilitate tests and examination of its glucose intravenous fluid products to be conducted. Reports of testing and examination so far conducted show that the above side-effects were not caused by its glucose intravenous fluid products, but further tests and examination are now being conducted and it is expected that all such other test results may be obtained in about two weeks’ time.

If and when there is any further progress of the above matters, the Company will make further announcement in accordance with the Listing Rules.

**Shareholders and potential investors in the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by the Company on a voluntary basis.

By Order of the Board  
**Asia Resources Holdings Limited**  
**Zhou Yu Kang**  
Chairman

Hong Kong, 31 October 2008

*As at the date of this announcement, the executive directors of the Company are Mr. Zhou Yu Kang, Mr. Chim Kim Lun, Ricky, Mr. Chan Sung Wai, Mr. Lin Dong and Mr. Yang Jianxin, and the independent non-executive directors are, Mr. Ngai Sau Chung Howard, Mr. Lin Ye and Mr. Zhang Xiufu.*

*\* For identification only*